吸入式托布拉米辛EEG粉末配方用于治疗由Pseudomonas aeruginosa引起的肺部感染
Rudra Pangeni1, Surendra Poudel1, Mohammad A M Momin1
1Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA.
International journal of pharmaceutics
|July 25, 2024
概括
这项研究开发了一种新型的托布拉米辛干粉喷雾剂,使用辅助剂增强生长技术和一种新的大鼠喷气式干粉灌气器. 新系统有效地减少了老鼠的Pseudomonas aeruginosa肺部感染.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
- 呼吸系统医学 呼吸系统医学
背景情况:
- 肺部抗生素输送提供高局部度的囊性纤维化肺部感染.
- 治疗的有效性取决于肺部防御,配方和药物-设备组合.
- 现有的用于动物模型的干粉吸气器是不可用的.
研究的目的:
- 使用辅助剂增强生长 (EEG) 技术开发和评估一种新的托布拉米辛 (Tobi) 干粉喷雾剂.
- 评估Tobi-EEG配方的体外和体内气溶性能.
- 为临床前研究开发和验证一种新的老鼠喷气式干粉吸气器 (Rat AJ DPI).
主要方法:
- 准备好的Tobi-EEG干粉气溶配方.
- 评估了体外和体内的气溶性能.
- 建立了一个由Pseudomonas aeruginosa诱导的肺部感染的老鼠模型.
- 开发并描述了用于粉末输送的鼠 AJ DPI.
- 评估了Tobi-EEG通过老鼠AJ DPI的肺沉积和分布.
- 在治疗后的老鼠气管和肺部中量化细菌负载 (CFU计数).
主要成果:
- 新型液体气溶剂显示了可比的感染形状,但细菌负载较低.
- 对于Tobi-EEG,Rat AJ DPI实现了高排放 (68-70%) 和高肺沉积效率 (79-86%).
- 在所有老鼠肺叶中观察到Tobi-EEG的均分布.
- 通过老鼠AJ DPI输送的Tobi-EEG显著降低了受感染老鼠的细菌CFU计数 (p < 0.05为2 mg,p < 0.001为5 mg).
结论:
- 小说"老鼠AJ DPI"提供的Tobi-EEG配方是一种有效的策略,用于治疗大鼠模型中的细菌性肺部感染.
- 这种新的药物-设备组合解决了临床前干粉吸入研究中的差距.
- 开发的系统显示了未来肺部抗生素研究和开发的前景.
更多相关视频
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
40.6K
04:59Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
Published on: August 18, 2023
833
相关概念视频
01:28Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
01:23Inhaled Medications
248
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
248
01:29Pulmonary Tuberculosis I
228
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
228
01:28Pneumonia IV: Management
315
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
315
01:28Pulmonary Tuberculosis II
215
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
215
01:25Transmission-based Precautions II: Airborne and Protective Environment
1.2K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.2K